All In Biotech

Drug Trial Radar · NCT07365319

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Jun 15, 2026

Primary completion

Dec 31, 2035

Study completion Dec 31, 2040

Sponsor

Lead sponsor
Eikon TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jan 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Conditions

  • Non Small Cell Lung Cancer (Squamous or Non Squamous)
  • Stage 4 NSCLC

Interventions

  • EIK1001Drug

    EIK1001 is a Toll like receptor 7/8 (TLR 7/8) dual agonist

  • Pembrolizumab (KEYTRUDA®)Drug

    PD-1 inhibitor

  • PlaceboDrug

    Placebo control

  • Paclitaxel + CarboplatinDrug

    SOC Chemotherapy for squamous NSCLC

  • Nab-paclitaxel + CarboplatinDrug

    SOC Chemotherapy for squamous NSCLC

  • Pemetrexed + Cisplatin /CarboplatinDrug

    SOC Chemotherapy for non-squamous NSCLC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Through study completion, up to 6 years
  2. Overall survival (OS)Time frame: Through study completion, up to 10 years
  3. Objective Response (OR)Time frame: Through study completion, up to 6 years

Locations

52 sites in 14 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center, P.C.

    Daphne, Alabama · Recruiting

  • Los Angeles Cancer Network

    Glendale, California · Recruiting

  • Providence St. Joseph Hospital

    Orange, California · Recruiting

  • Rocky Mountain Cancer Centers, LLP

    Pueblo, Colorado · Recruiting

  • Omnicure Clinical Research

    Doral, Florida · Recruiting

  • Florida Clinical Trials Group

    Plantation, Florida · Recruiting

  • Florida Clinical Trials Group - Tamarac

    Tamarac, Florida · Recruiting

  • OSF Saint Francis Medical Center

    Peoria, Illinois · Recruiting

  • University of New Mexico - Comprehensive Cancer Center

    Albuquerque, New Mexico · Recruiting

  • NYU Langone Hospital Long Island

    Mineola, New York · Recruiting

  • NYU Langone Hospital Manhattan

    New York, New York · Recruiting

  • Jacobi Medical Center - Albert Einstein College of Medicine

    The Bronx, New York · Recruiting

  • White Plains Hospital

    White Plains, New York · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • The Center for Cancer and Blood Disorders

    Fort Worth, Texas · Recruiting

  • Blue Ridge Cancer Center

    Blacksburg, Virginia · Recruiting

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia · Recruiting

  • Shenandoah Oncology P.C.

    Winchester, Virginia · Recruiting

  • Fundación de Estudios Clínicos

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Cancer Care Northern Beaches

    Frenchs Forest, New South Wales, Australia · Recruiting

  • Calvary Mater Newcastle Hospital

    Waratah, New South Wales, Australia · Recruiting

  • Peninsula and Southeast Oncology (PASO) Medical

    Frankston, Victoria, Australia · Recruiting

  • Sunshine Hospital - Western Health

    Saint Albans, Victoria, Australia · Recruiting

  • Kepler Universitaetsklinikum

    Linz, Austria · Recruiting

  • Centre Hospitalier Universitaire Brugmann

    Brussels, Belgium · Recruiting

  • Hospital Brasília Unidade Lago Sul

    Brasília, Brazil · Recruiting

  • CRIO - Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazil · Recruiting

  • Hospital Evangélico de Cachoeiro de Itapemirim

    Cachoeiro de Itapemirim, Espírito Santo, Brazil · Recruiting

  • Nucleo de Oncologia da Bahia

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Oncoclinicas Rio de Janeiro

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • Clinica de Hematologia e Oncologia Viver Ltda

    Santa Maria, Rio Grande do Sul, Brazil · Recruiting

  • Katholische Marienkrankenhaus gGmbH

    Hamburg, Germany · Recruiting

  • University Hospital Carl Gustav Carus Dresden

    Dresden, Saxony, Germany · Recruiting

  • Henry Dunant Hospital Center

    Athens, Greece · Recruiting

  • 4th Department of Medical Oncology, European Interbalkan Medical Center

    Thessaloniki, Greece · Recruiting

  • Hospital Genesis

    Thessaloniki, Central Macedonia, Greece · Recruiting

  • Policlinico Campus Bio-Medico

    Roma, Italy · Recruiting

  • GCPMED Sp. z o.o., Centrum Medyczne iMed24

    Krakow, Lesser Poland Voivodeship, Poland · Recruiting

  • Medisprof Cancer Center

    Cluj-Napoca, Cluj, Romania · Recruiting

  • The Medical Oncology Centre of Rosebank

    Saxonwold, Gauteng, South Africa · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.